Saint Barthélemy
Latest News
According to WHO, as of 25 November 2024, a total of 11’ 634 confirmed Oropouche cases, including two deaths, have been reported in the Region of the Americas, across ten countries and one territory: Bolivia (356 cases), Brazil (9563 cases, including two deaths), Canada (two imported cases), Cayman Island (one imported case), Colombia (74 cases), Cuba (603 cases), Ecuador (two cases), Guyana (two cases), Panama (one case), Peru (936 cases), and the United States of America (94 imported cases). Additionally, imported Oropouche cases have been reported in countries in the European Region (30 cases).
In addition, As of 7 December 2024, two adult cases of Oropouche virus disease have been reported by health officials on Barbados.
Oropouche virus
- is spread primarily by the bite of infected midges (small flies) and mosquitoes (Culex quinquefasciatus).
- has been found in semen, but it is unknown if it can be spread through sex. No cases of sexual transmission of Oropouche virus have yet been reported.
- transmission to the unborn child has been reported. The extent of possible malformations or death in the unborn baby in the context of an OROV outbreak situation is currently still unclear and is being investigated.
- Illness can occur in people of any age and is often mistaken for dengue.
- There is no vaccine and not specific treatment available
Prevention: The best way to protect yourself from Oropouche is to prevent insect bites 24/7 (also against other mosquito-borne diseases such as Dengue, Zika, Chikungunya), see factsheet.
Pregnant women and women planning to be pregnant should be provided with comprehensive information during pre-travel consultation on the Oropouche virus outbreaks and the potential of miscarriage, fetal malformation or death.
In the event of increased OROV transmission (= declared as an OROV outbreak according CDC Level 2 Travel Health Notice for Oropouche), the Swiss Expert Commission for Travel Medicine recommends:
- Pregnant women should re-consider non-essential travel
- If travel is unavoidable, strictly adhere to insect prevention measures (see LINK) and talk to your health care provider.
- To avoid sexual transmission: males should consider using condoms during travel and up to 2 months after return.
Between epidemiological week (EW) 1 and EW 35 of 2024, 38 confirmed human cases including 19 deaths of yellow fever (YF) have been reported in 5 countries of the Americas Region: Bolivia (7 cases, including 4 with history of YF vaccination), Brazil (3 cases, including 1 case with history of YF vaccination in 2017), Colombia (8 cases, including 1 cases with history of YF vaccination), Guyana (2 cases), and Peru (18 cases). For details, see LINK.
Geographical distribution of municipalities with occurrence of yellow fever cases in humans in Bolivia, Brazil, Colombia, Guyana, and Peru, years 2022, 2023, and 2024 (as of EW 35):
(source image: PAHO Zika weekly report, accessed 19.11.2021) The high incidence in Guatemala compared to the other countries is striking. However, these numbers need to be interpreted with caution, as epidemiological surveillance may be limited due to the COVID-19 pandemic. Case numbers in the Caribbean are incomplete, see link for details.
Consequences for travelers
Currently, none of the above countries is classified as an area with a current outbreak (see CDC map). Prevention: Optimal mosquito protection is necessary around the clock (24/7): during the day against dengue, chikungunya, Zika and other viruses, at dusk and at night against malaria. If you should have a fever: take medication containing the ingredient paracetamol and make sure you drink enough fluids. Do not take any medication containing the ingredient acetylsalicylic acid (e.g. Aspirin®), as this may increase the risk of bleeding in the event of a dengue infection (see also factsheet dengue). If you have visited a malaria area and have a fever >37.5 °C, you should always exclude malaria by taking a blood smear on the spot. Visit a medical facility for this (see also factsheet malaria). Detailed information on Zika can be found in the Zika factsheet.
References
PAHO Zika weekly report, accessed 19.11.2021
The 'Pan American Health Organization' (PAHO) has reported 122,203 chikungunya fever cases in the Americas in the year 2021, compared to 103,000 cases reported for the entire year of 2020. Brazil accounts for the majority of cases (97%).
Chikungunya fever is a viral infection transmitted by Aedes mosquitoes. The disease is typically manifested by severe joint pain in the hands and feet, which can last for weeks or months in some patients.
Consequences for travelers
Optimal mosquito protection measures 24/7: during the day against dengue, chikungunya, Zika and other viruses, at dusk and at night against malaria. If you should have a fever: take medication containing the ingredient paracetamol and make sure you drink enough fluids. Do not take any medication containing the ingredient acetylsalicylic acid (e.g. Aspirin®), as this may increase the risk of bleeding in the event of a dengue infection (see also factsheet dengue). If you have visited a malaria area and have a fever >37.5 °C, you should always exclude malaria by taking a blood smear on the spot. Visit a medical facility for this (see also factsheet malaria).
References
General Information
- Although the public health emergency of international concern for COVID-19 was declared over on 5 May 2023, COVID-19 remains a health threat
- Adhere to the recommendations and regulations of your host country
- Check entry requirements of destination country: see regulary updated COVID-19 Travel Regulations Map of IATA (LINK)
Vaccinations for all travellers
- Hepatitis A vaccination is recommended for all travellers going to tropical or subtropical countries.
- Hepatitis A is a liver infection caused by a virus. It is also known as infectious jaundice.
- The virus is easily transmitted by contaminated food or water but can also be transmitted through sexual contact.
- A safe and very effective vaccine is available that affords long-lasting protection.
- Hepatitis A vaccination is recommended for all travelers going to tropical or subtropical countries, and for risk groups.
All travellers should have completed a basic immunisation and boosters according to the Swiss vaccination schedule, LINK.
All travellers should have completed a basic immunisation and boosters according to the Swiss vaccination schedule, LINK.
Travellers should be immune to chickenpox. Persons between 13 months and 39 years of age who have not had chickenpox and who have not received 2 doses of chickenpox vaccine should receive a booster vaccination (2 doses with minimum interval of 4 weeks), see Swiss vaccination schedule, LINK.
Vaccinations for some travellers
For administrative reasons, there is the following entry regulation of the country:
- Vaccination against yellow fever is required if arriving from countries with risk of yellow fever transmission and for travellers having transited for more than 12 hours through an airport of a country with risk of yellow fever transmission.
Exempt from this entry requirement:
- Children younger than 1 year of age.
- Yellow fever is a life-threatening viral infection. A highly effective vaccine is available.
- Vaccination is strongly recommended for all travellers to regions where yellow fever occurs, even if it is not a mandatory entry requirement of the country.
- A booster single booster dose is recommended for immuncompetent persons after 10 years.
- The yellow fever vaccination must be administered by an authorized doctor or center at least ten days before your arrival in the destination country with record in the yellow vaccination booklet ('International Certificate for Vaccination').
- For travellers who are pregnant, breastfeeding, or who have a condition that leads to immunosuppression, please consult a travel health advisor.
EKRM_Factsheet_Layperson_EN_Yellow-fever.pdf
EKRM_Factsheet_Layperson_EN_Mosquito-and-tick-bite-protection.pdf
For administrative reasons, there is the following entry regulation of the country:
- Vaccination against yellow fever is required if arriving from countries with risk of yellow fever transmission and for travellers having transited for more than 12 hours through an airport of a country with risk of yellow fever transmission.
Exempt from this entry requirement:
- Children younger than 1 year of age.
CDC Map: Yellow fever vaccine recommendations for the Americas
Footnotes
- Current as of November 2022. This map is an updated version of the 2010 map created by the Informal WHO Working Group on the Geographic Risk of Yellow Fever.
- In 2017, the Centers for Disease Control and Prevention (CDC) expanded its yellow fever vaccine recommendations for travelers going to Brazil because of a large outbreak in multiple states in that country. For more information and updated recommendations, refer to the CDC Travelers’ Health website.
- Yellow fever (YF) vaccination is generally not recommended for travel to areas where the potential for YF virus exposure is low. Vaccination might be considered, however, for a small subset of travelers going to these areas who are at increased risk for exposure to YF virus due to prolonged travel, heavy exposure to mosquitoes, or inability to avoid mosquito bites. Factors to consider when deciding whether to vaccinate a traveler include destination-specific and travel-associated risks for YF virus infection; individual, underlying risk factors for having a serious YF vaccine-associated adverse event; and country entry requirements.
- Yellow fever occurs in sub-Saharan Africa and South America and is transmitted by mosquitoes.
- Disease may be severe in unvaccinated travelers and death may occur in over 50%.
- A highly effective vaccine is available.
- Due to potentially severe side effects the vaccine is used with caution in immunocompromised or elderly individuals, as well as in pregnant women.
As against all mosquito-borne diseases, prevention from mosquito bites is during day and night (see “Insect and tick bite protection” factsheet). The available vaccine is highly efficacious and provides a long-term protection. It is recommended for people aged 9 months or older who are travelling to yellow fever endemic areas. In addition, providing proof of vaccination may be mandatory for entry into certain countries.
The vaccine is a live-attenuated form of the virus. In immunocompetent persons, protection starts about 10 days after the first vaccination. Reactions to yellow fever vaccine are generally mild and include headache, muscle aches, and low-grade fevers. Side effects can be treated with paracetamol but aspirin and other nonsteroidal anti-inflammatory drugs, for example ibuprofen or naproxen, should be avoided. On extremely rare occasions, people may develop severe, sometimes life-threatening reactions to the yellow fever vaccine – which is why this vaccine is used with caution in immunocompromised individuals, pregnant women and the elderly for safety reasons. Talk to your travel health advisor if you belong to this group.
Yellow Fever Info - Centers for Disease Control and Prevention: https://www.cdc.gov/yellowfever/index.html
Yellow Fever Info - European Centre for Disease Prevention and Control: https://www.ecdc.europa.eu/en/yellow-fever/facts
- Hepatitis B is a viral liver infection that is transmitted via contaminated blood or via sexual contact.
- A safe and very effective vaccine is available that affords life-long protection.
- Hepatitis B vaccination is recommended for all young people and at-risk travellers, especially if:
- You travel regularly or spend long periods of time abroad.
- You are at risk of practicing unsafe sex.
- You might undergo medical or dental treatment abroad, or undertake activities that may put you at risk of acquiring hepatitis B (tattoos, piercing, acupuncture in unsafe conditions).
- Covid-19 is a disease that affects the whole body, but mainly shows with respiratory symptoms such as cough and difficulty in breathing. It is caused by the SARS-CoV-2 virus.
- The infection is mainly spread through respiratory droplets and possibly aerosols when infected persons cough, sneeze, speak or sing without wearing a mask.
- The infection can be prevented very effectively by vaccination and an increasing number of vaccines are now approved and available for protection.
- Vaccination is recommended according to the Swiss recommendations of the Federal Office of Public Health (FOPH), see LINK.
- Furthermore, prevention relies heavily on people wearing face masks, on hand hygiene and on physical distancing (min. 1.5 m) if masks are not worn and people are not vaccinated.
- Influenza is common all over the world including sub-tropical and tropical countries.
- Vaccination offers the best protection.
- Vaccination against flu is recommended for all travellers who belong to an “at risk” group such as pregnant travellers, travellers with comorbidities, elderly people (>65 years), or who plan a a high-risk trip (e.g. cruise-ship, pilgrimage).
- The influenza vaccine does not offer protection against avian flu.
Other health risks
- Dengue fever is a viral disease that is disease that bite during daytime.
- The best way to prevent these diseases is to protect yourself from mosquito bites, see LINK!
- A vaccination (Qdenga®) against dengue is available.
- However, based on the data available, the Swiss Expert Committee for Travel Medicine (ECTM) currently recommends vaccination with Qdenga® only for travellers who have evidence of previous dengue infection and who will be exposed in a region with significant dengue transmission, for details see LINK.
- In case of fever: do not use any medication containing acetylsalicylic acid (e.g. Aspirin®, Alcacyl®, Aspégic®), as this can worsen bleeding in case of dengue infection.
- Read the following information for optimal travel preparation.
EKRM_Factsheet_Layperson_EN_Dengue.pdf
EKRM_Factsheet_Layperson_EN_Mosquito-and-tick-bite-protection.pdf
ECTM_Dengue_Vaccination_Statement_EN_Publication_Sept_2024.pdf
CDC Map: Distribution of dengue
- Dengue fever is the world's most common insect-borne infectious disease.
- Great attention should be paid to mosquito protection during the day!
- The disease can cause high fever, muscle and joint pain, and skin rashes. In rare cases, bleeding may occur. There is no specific treatment. Vaccination is recommended only for people with evidence of previous dengue infection.
- For personal safety, we strongly recommend that you inform yourself in detail about dengue.
Dengue fever is the most common insect-borne infectious disease worldwide. There are 4 known serotypes of dengue virus, so it is possible to be infected with dengue more than once. Approximately 1 in 4 infected individuals develop symptoms of dengue, resulting in high fever, muscle and joint pain, and skin rash. In rare cases, most often after a second infection, life-threatening bleeding and shock (severe drop of blood pressure) may occur.
In 3 out of 4 cases, an infection with the virus remains asymptomatic. After a short incubation period (5-8 days), 1 out of 4 infected people present an abrupt onset of fever, headache, joint, limb and muscle pain, as well as nausea and vomiting. Eye movement pain is also typical. A rash usually appears on the 3rd or 4th day of illness. After 4 to 7 days, the fever finally subsides but fatigue may persist for several days or weeks.
In rare cases, severe dengue can occur. Particularly susceptible are local children and seniors as well as people who have experienced a prior dengue infection. Tourists extremely rarely present with severe dengue. In the first days, the disease resembles the course of classic dengue fever, but on the 4th/5th day, and usually after the fever has subsided, the condition worsens. Blood pressure drops, and patients complain of shortness of breath, abdominal discomfort, nosebleeds, and mild skin or mucosal hemorrhages. In the most severe cases, life-threatening shock may occur.
There is no specific treatment for dengue virus infection. Treatment is limited to mitigation and monitoring of symptoms: fever reduction, relief of eye, back, muscle and joint pain, and monitoring of blood clotting and blood volume. Patients with severe symptoms must be hospitalised.
For treatment of fever or pain, paracetamol or acetaminophen are recommended (e.g. Acetalgin® Dafalgan®). Drugs containing the active ingredient acetylsalicylic acid (e.g. Aspirin®, Alcacyl®, Aspégic®) must be avoided.
Effective mosquito protection during the day and especially during twilight hours (i.e. sunset) is the best preventive measure:
- Clothing: Wear well-covered, long-sleeved clothing and long pants and treat clothing with insecticide beforehand (see factsheet “prevention of arthropod bites”).
- Mosquito repellent: Apply a mosquito repellent to uncovered skin several times a day (see factsheet “prevention of arthropod bites”).
- Environmental hygiene: Do not leave containers with standing water (coasters for flower pots, etc.) in your environment to avoid mosquito breeding sites.
For further information, please refer to the factsheet on "Mosquito and tick bite protection".
Note on the dengue vaccine Qdenga®:
- Based on the data available, many European countries, as well as the Swiss Expert Committee for Travel Medicine (ECTM), currently recommend vaccination with Qdenga® only for travelers who have evidence of a previous dengue infection and who will be exposed in a region with significant dengue transmission. This is a precautionary decision, since the current data also include the possibility that people who are vaccinated with Qdenga® before a first dengue infection may experience a more severe course of the disease. A consultation with a specialist in tropical and travel medicine is recommended.
Consistent mosquito protection during the day (see above) is still considered the most important preventive measure against dengue!
Of note
- Do not take any products containing the active ingredient acetylsalicylic acid (e.g. Aspirin®, Alcacyl®, Aspégic®) if you have symptoms, as they increase the risk of bleeding in the event of a dengue infection!
- However, do not stop taking medications containing acetylsalicylic acid if it is already part of your regular treatment for an underlying condition.
- Do not take any products containing the active ingredient acetylsalicylic acid (e.g. Aspirin®, Alcacyl®, Aspégic®) if you have symptoms, as they increase the risk of bleeding in the event of a dengue infection!
- However, do not stop taking medications containing acetylsalicylic acid if it is already part of your regular treatment for an underlying condition.
- Chikungunya is a viral disease transmitted by mosquitoes that bite during daytime.
- As a prevention measure, great attention should be given to protection from mosquito bites.
- There is neither a vaccination nor a specific medication against chikungunya for travellers.
- In case of fever: do not use acetylsalicylic acid (e.g. Aspirin®, Alcacyl®, Aspégic®) as this can worsen bleeding in case of dengue infection.
- Read the following information for optimal travel preparation.
EKRM_Factsheet_Layperson_EN_Chikungunya.pdf
EKRM_Factsheet_Layperson_EN_Mosquito-and-tick-bite-protection.pdf
CDC Map: Distribution for Chikungunya
- Chikungunya is a viral disease transmitted by Aedes mosquitoes.
- Chikungunya can be prevented by protection against mosquito bites.
- It typically presents with severe joint pain of the hands and feet. In a few patients, these may persist for weeks or months.
The infection may present with some or all of the following symptoms: sudden onset of high-grade fever, chills, headache, redness of eyes, muscle and joint pain, and rash. The rash usually occurs after the onset of fever and typically involves the trunk and extremities, but can also include the palms, soles of the feet, and the face.
Often fever occurs in two phases of up to one week duration, with an interval of one to two fever-free days in between. The second phase may present with much more intense muscle and joint pain, which can be severe and debilitating. These symptoms are typically bilateral and symmetric and mainly involve hands and feet, but may also involve the larger joints, such as the knees or shoulders.
About 5-10% of infected people continue to experience severe joint pain even after the fever has subsided, in some cases lasting up to several months or, albeit rare, even years.
- FOPH Switzerland: https://www.bag.admin.ch/bag/de/home/krankheiten/krankheiten-im-ueberblick/chikungunya.html
- WHO - Chikungunya fact sheet: https://www.who.int/news-room/fact-sheets/detail/chikungunya
- Center for Disease Control and Prevention (CDC): https://www.cdc.gov/chikungunya/index.html
- Marburg virus disease is a rare but severe hemorrhagic fever.
- The disease spreads through contact with infected animals or people.
- Symptoms can be similar to other tropical diseases
- There is no licensed treatment or vaccine for Marburg disease, and
- Please have a look to the factsheet below.
- Marburg virus disease is a rare but severe hemorrhagic fever.
- The disease spreads through contact with infected animals or people.
- Symptoms can be similar to other tropical diseases
- There is no licensed treatment or vaccine for Marburg disease, and
- Prevention measures are important to follow, see below.
The incubation period (time between infection and onset of symptoms) ranges from a 2 to 21 days (usually 5 to 10 days). The onset of MVD is usually abrupt, with initially non-specific, flu-like symptoms such as a high fever, severe headache, chills and malaise. Rapid worsening occurs within 2–5 days for more than half of patients, marked by gastrointestinal symptoms such as anorexia, abdominal discomfort, severe nausea, vomiting, and diarrhoea. As the disease advances, clinical manifestations can become more severe and include liver failure, delirium, shock, bleeding (hemorrhaging), multi-organ dysfunction and death.
In case of symptoms
If think that you have had an exposure at risk and develop fever with nonspecific symptoms such as chills, headache, muscle pain, malaise or abdominal pain:
- you should separate yourself from others (isolate) immediately and
- immediately seek medical advice by contacting the in-country hotline by phone or contact a tropical institute or university hospital infectious disease unit.
- alert the healthcare providers of your recent travel to an area with a Marburg outbreak.
The risk for travellers is very low if the below precautions are followed, but it is high for family members and caregivers who have contact with sick people.
General precautions during travel to affected areas:
- Wash your hands regularly and carefully using soap and water (or alcohol gel if soap is unavailable).
- Avoid contact with sick people who have symptoms, such as fever, muscle pain, and rash.
- Avoid contact with blood and other body fluids
- Avoid visiting healthcare facilities in the MVD-affected areas for nonurgent medical care or non-medical reasons.
- Avoid contact with dead bodies or items that have been in contact with dead bodies, participating in funeral or burial rituals, or attending a funeral or burial.
- Avoid handling, cooking, or eating bush/wild meat (meat of wild/feral mammals killed for food).
- Wash and peel fruit and vegetables before consumption.
- Avoid visiting mines or bat caves and contact with all wild animals; alive or dead, particularly bats.
- If you decide to visit mines or caves inhabited by fruit bat colonies, wear gloves and other appropriate protective clothing, including masks and eye protection.
- Practice safer sex.
- Swiss Federal Office of Public Health: LINK
- European Center for Disease Control and Prevention (ECDC): Marburg virus disease
- US Center for Disease Control and Prevention (CDC): About Marburg Disease
- World Health Organization: Marburg Virus Disease
- Mpox is a viral disease that typically causes a rash, swollen lymph nodes and fever.
- An emerging variant is spreading rapidly in eastern D.R. Congo and neighbouring countries, leading the WHO to declare a new Public Health Emergency International (PHEIC) in August 2024.
- Close physical contact (sexual or non-sexual) is the main route of transmission.
- The disease is usually mild. Children, pregnant women and people with weakened immune systems are most at risk of complications.
- Take general precautions (see factsheet) to prevent the disease.
- There is a vaccination against Mpox, but it is currently only available for people at high risk.
- Mpox is a viral disease that typically causes a rash, swollen lymph nodes and fever.
- An emerging variant is spreading rapidly in eastern D.R. Congo and neighboring countries prompting a new WHO declaration of a public health emergency of international concern (PHEIC), as of August 14th 2024.
- Close physical contact (sexual or non-sexual) is the main mode of transmission.
- The disease generally follows a mild course. Children, pregnant women, and people with weak immune systems are the most at risk of complications.
- Vaccination against mpox is available, but limited to groups at high risk of exposure.
Mpox has been commonly found in West and Central Africa for many years where the suspected reservoir - small mammals - is endemic. There are two types of Monkeypox virus called ‘clades’ that cause the disease mpox - clade I in Central Africa and clade II in West Africa. Since the end of smallpox vaccination campaigns in the early 1980’s, cases of mpox have increased, slowly at first and significantly in the last 5-10 years, especially in the Democratic Republic of Congo (DRC).
In 2022, a new emerging subclade of clade II was responsible for a global epidemic that spread mainly through sexual contact among men who have sex with men. It resulted in the first public health emergency of international concern (PHEIC) declared by the WHO until 2023. Although the clade II epidemic is now under control, this virus variant continues to circulate worldwide.
In 2024, the continued spread of mpox clade I in endemic regions of Central Africa, particularly in the DRC, and the emergence of a new subclade Ib in Eastern DRC and neighboring countries have raised global concern and prompted the WHO to declare a PHEIC for the second time in two years. The current geographical spread of the mpox clade Ib variant occurs via commercial routes through sexual contact (e.g. sex workers), followed by local transmission in households and other settings (which is becoming increasingly important).
Animal to human transmission
Mpox can spread from animal to human when they come into direct contact with an infected animal (rodents or primates).
Human to human transmission
Mpox can be spread from person to person through close physical contact (sexual and non-sexual contact) with someone who has symptoms of mpox. Skin and mucous membrane lesions, body fluids, and scabs are particularly infectious. A person can also become infected by touching or handling clothing, bedding, towels, or objects such as eating utensils/dishes that have been contaminated by contact with a person with symptoms. Household members, family caretakers, and sexual partners of a confirmed case of mpox are at higher risk for infection as are health care workers who treat a case without adequate personal protection.
The incubation period (time between infection and onset of symptoms) ranges from a few days up to 3 weeks. Mpox causes a rash / skin eruption that can be painful associated with swollen lymph nodes and fever. Fever may start already before the rash phase. Other symptoms include muscle aches, back pain, and fatigue. The rash may be localized or generalized, with few or hundreds of skin lesions. It mainly affects the face, the trunk and the palms of hand and soles of the feet. It can also be present in genital areas and on mucous membranes such as in the mouth and throat. Symptoms usually last 2 to 4 weeks and the person remains contagious until all lesions have healed (once the cabs have fallen off).
Complications include secondary bacterial infections, infections of the lung and brain and involvement of other organs, still birth and others. Children, pregnant women, and people with weak immune systems are at higher risk to develop a severe form of mpox.
The majority of person with mpox recovers spontaneously and do not need specific antiviral treatment. Care management consists of relieving pain and other symptoms and preventing complications (e.g., superinfection). Several antiviral treatments are studied in various countries and may be used in trials or in clinical situations according to the recommendations of national medical societies.
In case of symptoms:
- Seek medical attention immediately
- If you are diagnosed with mpox
- Please stay at home (isolate yourself) until your mpox rash has healed and a new layer of skin has formed. Staying away from other people and not sharing things you have touched with others will help prevent the spread of mpox. People with mpox should regularly clean and disinfect the spaces they use to limit household contamination.
- Wash your hands often with soap and water or an alcohol-based hand sanitiser containing at least 60% alcohol.
- You should not have sex while symptomatic and while you have lesions or symptoms. Use condoms for 12 weeks after infection. This is a precaution to reduce the risk of spreading the virus to a partner.
- For more information on what do if you are sick, see CDC LINK.
General precautions:
- Worldwide:
- avoid close, skin-to-skin contact with people who have or may have mpox or people who have a rash (e.g., pimples, blisters, scabs).
- Wash your hands often with soap and water or an alcohol-based hand sanitiser containing at least 60% alcohol.
- Avoid touching potentially contaminated personal items such as cups, bedding/clothing, towels or sharing eating utensils/cups, food or drink with a person who has, or may have mpox.
- Avoid sex with sick persons; use of condoms for up to 12 weeks if you sexual partner have had mpox.
- Follow advice of local authorities.
- When travelling to endemic / epidemic areas in Africa, in addition to above mentioned general precautions:
- Avoid contact with and animals in areas where mpox regularly occurs.
- Avoid eating or preparing meat from wild animals (bushmeat) or using products (creams, lotions, powders) derived from wild animals.
Vaccination:
There are several vaccines against mpox (e.g. Jynneos®, manufacture Bavarian Nordic). The Bavarian Nordic vaccine was originally developed to fight against smallpox, but offers a cross-protection against mpox. In Switzerland, the Jynneos® vaccine has been licensed by Swissmedic since 2024. Groups at risk (e.g., men who have sex with men or transgender people with multiple sex partners) are eligible for vaccination since 2022 and this recommendation remains unchanged (see FOPH recommendations). In light of the epidemiological situation in Africa in 2024, the Swiss Expert Committee for Travel Medicine recommends vaccination against mpox for professionals who are / will be in contact with suspect mpox patients or animals in endemic/epidemic regions or who work in a laboratory with the virus (for updates, see news).
The risk to the general population and travelers (tourists) is considered extremely low if the above-mentioned general precautions are followed and vaccination is not recommended.
- Seek medical attention immediately.
- Mpox is not a sexual transmitted disease in the strict sense, physical contact with a person with symptoms of mpox (rash at any stage) is sufficient to transmit the disease. Condoms do not protect you from getting mpox!
There is a risk of arthropod-borne diseases other than malaria, dengue, chikungunya or zika in sub-/tropical regions, and some areas of Southern Europe. These include the following diseases [and their vectors]:
- in Europe
- Borreliosis, FSME (= tick-borne encephalitis), rickettsiosis [ticks]
- Leishmaniasis [sand flies]
- West-Nile fever [mosquitoes]
- in Africa
- Rickettsiosis, in particular African tick bite fever [ticks]
- Leishmaniasis [sand flies]
- African trypanosomiasis = sleeping sickness [tsetse flies]
- West-Nile fever [mosquitoes]
- in Asia
- Scrub typhus [mites]
- Rickettsiosis [fleas or ticks]
- Leishmaniasis [sand flies]
- West-Nile fever [mosquitoes]
- Crimea-Congo-hemorrhagic fever [ticks]
- in North and Latin America
- Rickettsioses and in particular Rocky Mountain spotted fever [ticks]
- Leishmaniasis and Carrion's disease [sand flies]
- American trypanosomiasis = Chagas disease [triatomine bugs]
- West Nile fever [mosquitoes]
- There are other important travel related health risks such as diarrhoea, road traffic accidents, air pollution and more.
- For more information, see the section "Healthy Travelling".